ATE489099T1 - Aminozucker, chondroitin und s-adenosylmethionin enthaltende zusammensetzungen - Google Patents
Aminozucker, chondroitin und s-adenosylmethionin enthaltende zusammensetzungenInfo
- Publication number
- ATE489099T1 ATE489099T1 AT07075664T AT07075664T ATE489099T1 AT E489099 T1 ATE489099 T1 AT E489099T1 AT 07075664 T AT07075664 T AT 07075664T AT 07075664 T AT07075664 T AT 07075664T AT E489099 T1 ATE489099 T1 AT E489099T1
- Authority
- AT
- Austria
- Prior art keywords
- composition
- salts
- chondroitin
- sulfate
- connective tissue
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title abstract 3
- 229960001570 ademetionine Drugs 0.000 title abstract 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 title abstract 3
- 229920002567 Chondroitin Polymers 0.000 title abstract 2
- 150000002337 glycosamines Chemical class 0.000 title abstract 2
- 210000002808 connective tissue Anatomy 0.000 abstract 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 3
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 abstract 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- REEBJQTUIJTGAL-UHFFFAOYSA-N 3-pyridin-1-ium-1-ylpropane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC=C1 REEBJQTUIJTGAL-UHFFFAOYSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229920000288 Keratan sulfate Polymers 0.000 abstract 1
- 102000011782 Keratins Human genes 0.000 abstract 1
- 108010076876 Keratins Proteins 0.000 abstract 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960003237 betaine Drugs 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
- 229940019765 dermatin Drugs 0.000 abstract 1
- 108700003601 dimethylglycine Proteins 0.000 abstract 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 150000002301 glucosamine derivatives Chemical class 0.000 abstract 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 1
- 229910052748 manganese Inorganic materials 0.000 abstract 1
- 239000011572 manganese Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 229940045999 vitamin b 12 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/845,852 US6255295B1 (en) | 1996-12-23 | 1997-04-28 | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE489099T1 true ATE489099T1 (de) | 2010-12-15 |
Family
ID=25296238
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98915591T ATE425757T1 (de) | 1997-04-28 | 1998-04-17 | Aminozucker, glycosaminoglycan oder glycosaminoglycan-ahnliche verbindungen und s- adenosylmethionin |
AT07075664T ATE489099T1 (de) | 1997-04-28 | 1998-04-17 | Aminozucker, chondroitin und s-adenosylmethionin enthaltende zusammensetzungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98915591T ATE425757T1 (de) | 1997-04-28 | 1998-04-17 | Aminozucker, glycosaminoglycan oder glycosaminoglycan-ahnliche verbindungen und s- adenosylmethionin |
Country Status (13)
Country | Link |
---|---|
US (1) | US6255295B1 (de) |
EP (2) | EP1849471B1 (de) |
AT (2) | ATE425757T1 (de) |
AU (1) | AU747595B2 (de) |
CA (3) | CA2286552C (de) |
CY (1) | CY1109064T1 (de) |
DE (2) | DE69840668D1 (de) |
DK (1) | DK0979090T3 (de) |
ES (2) | ES2324565T3 (de) |
HK (1) | HK1114774A1 (de) |
NZ (1) | NZ500025A (de) |
PT (1) | PT979090E (de) |
WO (1) | WO1998048816A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010000472A1 (en) * | 1998-02-27 | 2001-04-26 | Nutramax Laboratories, Inc. | L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage |
JP2002516866A (ja) * | 1998-06-04 | 2002-06-11 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | 結合組織を治療し修復するためのアミノ糖、グリコサミノグリカンおよびs−アデノシルメチオニン組成物 |
CA2333755C (en) * | 1998-06-05 | 2012-11-27 | Nutramax Laboratories, Inc. | The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
EP1762247A1 (de) * | 1998-06-05 | 2007-03-14 | Nutramax Laboratories, Inc. | Verwendung von Anabolika, antikatabolischen Mitteln, Antioxidationsmittel und Analgetika zum Schutz sowie zur Behandlung und Wiederherstellung von Bindegewebe bei Menschen und Tieren |
US6656925B2 (en) * | 1998-09-09 | 2003-12-02 | Advanced Medical Instruments | Composition and method of treating arthritis |
US20020018787A1 (en) * | 1999-05-21 | 2002-02-14 | Roger V. Kendall | Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
AU727355B3 (en) * | 1999-07-21 | 2000-12-14 | Bomac Laboratories Limited | Compositions addressing inflammation and/or degenerative disorders |
US6524609B1 (en) * | 1999-08-18 | 2003-02-25 | Nutri-Vet, Llc | Treating arthritis in animals with dietary supplements |
AU7863400A (en) * | 1999-10-08 | 2001-04-23 | Pharmnseas, Inc. | Nutraceutical products containing same and dietary supplements and method of manufacture and use thereof |
DE20004010U1 (de) | 2000-03-02 | 2000-06-21 | Febena Pharma GmbH, 50825 Köln | Diätische Zusammensetzung mit einem Gehalt an Glycosaminoglycanen |
US20050282774A1 (en) * | 2000-10-31 | 2005-12-22 | Eek Bjorn C | Method and pharmaceutical to treat spinal discs |
CA2435637A1 (en) | 2001-01-23 | 2002-08-01 | Massachusetts Institute Of Technology | Solid- and solution -phase synthesis of heparin and other glycosaminoglycans |
US6689391B2 (en) | 2001-03-30 | 2004-02-10 | Council Of Scientific & Industrial Research | Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses |
US6916492B2 (en) | 2001-03-30 | 2005-07-12 | Council Of Scientific & Industrial Research | Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses |
BRPI0101486B1 (pt) * | 2001-04-17 | 2017-09-19 | Cristália Produtos Químicos Farmacêuticos Ltda. | Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns |
US20030134825A1 (en) * | 2002-01-03 | 2003-07-17 | Robert Bahoshy | Food product supplemented with proteoglycan precursors |
US20030138543A1 (en) * | 2002-01-03 | 2003-07-24 | Bradley T. Baumann | Food product supplemented with proteoglycan precursors |
US7387796B2 (en) * | 2002-01-30 | 2008-06-17 | Hebert Rolland F | Stable compositions of S-adenosyl-l-methionine with dextran |
WO2003068249A1 (en) * | 2002-02-15 | 2003-08-21 | Ocean Nutrition Canada Limited | Shark cartilage extracts and use thereof for immunomodulation |
US20030170374A1 (en) * | 2002-03-05 | 2003-09-11 | Robert Bahoshy | Condiments including nutritional supplements |
ATE311889T1 (de) * | 2002-04-19 | 2005-12-15 | Astion Dev As | Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungen |
US7504387B2 (en) * | 2002-10-16 | 2009-03-17 | Arthrodynamic Technologies, Animal Health Division, Inc. | Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis |
US7485629B2 (en) * | 2002-10-16 | 2009-02-03 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treatment of joint damage |
DE10260958A1 (de) * | 2002-12-20 | 2004-07-08 | Sustech Gmbh & Co. Kg | Kompositmaterialien aus Calciumverbindungen und Glucuronsäure- und/oder Iduronsäurehaltigen Polysacchariden |
US6946551B2 (en) * | 2003-03-12 | 2005-09-20 | New Life Resources, Llc | Preparation of hyaluronic acid from eggshell membrane |
US20040180025A1 (en) * | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
US20080063677A1 (en) * | 2004-03-10 | 2008-03-13 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
US20050176807A1 (en) * | 2004-02-09 | 2005-08-11 | Friesen Kim G. | Composition and method for use in cartilage affecting conditions |
US20050176674A1 (en) * | 2004-02-09 | 2005-08-11 | Friesen Kim G. | Composition and method for use in cartilage affecting conditions |
US8377904B2 (en) * | 2004-02-09 | 2013-02-19 | Hill's Pet Nutrition, Inc. | Composition and method for use in cartilage affecting conditions |
US8580315B2 (en) * | 2004-03-10 | 2013-11-12 | Esm Technologies, Llc | Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations |
CA2616230A1 (en) * | 2005-07-22 | 2007-02-01 | Trf Pharma, Inc. | Method for treating sickle cell disease and sickle cell disease sequelae |
US9492381B1 (en) | 2005-11-10 | 2016-11-15 | Reyn Pharma, Llc | Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis |
US8598144B1 (en) | 2005-11-10 | 2013-12-03 | Reyn Pharma, Llc | Method of administering hyaluronan formulation for the amelioration of osteoarthritis |
ES2913483T3 (es) | 2006-04-03 | 2022-06-02 | Ceva Animal Health Pty Ltd | Formulaciones estabilizadas de polisulfato de pentosano (PPS) |
JP5175481B2 (ja) * | 2006-10-23 | 2013-04-03 | エーザイフード・ケミカル株式会社 | 軟骨再生促進剤 |
BRPI0812774A2 (pt) * | 2007-06-06 | 2014-12-02 | Novus Int Inc | Suplementos alimentares para promoção de crescimento, reparo e manutenção de osso e juntas |
US7947662B2 (en) * | 2008-02-20 | 2011-05-24 | Gnosis S.P.A. | Folates, compositions and uses thereof |
US8163716B1 (en) | 2008-06-30 | 2012-04-24 | Smith James D | Method of administering hyaluronan formulation for the amelioration of osteophytes |
US8178511B1 (en) | 2008-07-02 | 2012-05-15 | Smith James D | Method of administering hyaluronan formulation for the amelioration of osteopenia |
US9180089B2 (en) * | 2009-09-23 | 2015-11-10 | Glenpharma Ab | Compositions and methods for inducing or enhancing connective tissue repair |
FR2996137B1 (fr) * | 2012-10-01 | 2017-10-27 | Sp2L | Composition comprenant de l'acide hyaluronique, du manganese et de la vitamine c |
CN112955115B (zh) | 2018-11-02 | 2023-06-30 | 联合利华知识产权控股有限公司 | 生物能烟酸甘油酯、组合物和使用其的方法 |
IT202100030935A1 (it) | 2021-12-09 | 2023-06-09 | Fidia Farm Spa | Compresse comprendenti condroitin solfato, glucosamina cloridrato e vitamina c per il trattamento di danni cartilaginei, tendinei, ossei |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3232836A (en) | 1959-08-24 | 1966-02-01 | Pfizer & Co C | Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine |
US3371012A (en) | 1964-08-07 | 1968-02-27 | Seikagaku Kogyo Co Ltd | Preservative for eye graft material |
DE1792346C3 (de) | 1968-08-22 | 1980-10-23 | Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien) | Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen |
IT1044707B (it) | 1968-10-26 | 1980-04-21 | Rotta Research Lab | Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi |
JPS5027884A (de) | 1973-07-12 | 1975-03-22 | ||
US4006224A (en) | 1975-09-29 | 1977-02-01 | Lescarden Ltd. | Method and agent for treating inflammatory disorders of the gastrointestinal tract |
US4378224A (en) | 1980-09-19 | 1983-03-29 | Nimni Marcel E | Coating for bioprosthetic device and method of making same |
US5180715A (en) | 1980-11-17 | 1993-01-19 | The Regents Of The University Of California | Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate |
US4486416A (en) | 1981-03-02 | 1984-12-04 | Soll David B | Protection of human and animal cells subject to exposure to trauma |
IT1137892B (it) | 1981-08-24 | 1986-09-10 | Bioresearch Srl | Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo |
IT1137640B (it) | 1981-08-24 | 1986-09-10 | Bioresearch Srl | Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo |
US4473551A (en) | 1982-08-23 | 1984-09-25 | Faxon Pharmaceuticals, Inc. | Anti-inflammatory composition |
FR2543145B1 (fr) | 1983-03-24 | 1986-10-17 | Sanofi Sa | Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante |
IT1173992B (it) | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale |
IT1173990B (it) | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale |
US4711780A (en) | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
DE3422407A1 (de) | 1984-06-16 | 1986-03-06 | B. Braun Melsungen Ag, 3508 Melsungen | Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma |
DE3432661A1 (de) | 1984-09-05 | 1986-03-06 | Albert Prof. Dr. 6907 Nußloch Landsberger | Carcinom-therapeutikum |
US4647453A (en) | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
FR2572731B1 (fr) | 1984-11-07 | 1987-03-06 | Sanofi Sa | Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale |
SE8501723L (sv) | 1985-04-09 | 1986-10-10 | Pharmacia Ab | Preparation att anvendas vid behandling av ledinflammation |
US4707354A (en) | 1985-06-17 | 1987-11-17 | Alpen Tau, Inc. | Mature skin treatment and protectant compositions and methods of using same |
US4772591A (en) | 1985-09-25 | 1988-09-20 | Peritain, Ltd. | Method for accelerated wound healing |
DE3602670A1 (de) | 1986-01-29 | 1987-07-30 | Speck Ulrich | Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen |
US4983580A (en) | 1986-04-04 | 1991-01-08 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
US4966890A (en) | 1986-04-04 | 1990-10-30 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
US4820693A (en) | 1986-05-22 | 1989-04-11 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
US5385938B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of using glycolic acid for treating wrinkles |
US5091171B2 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
CA1327354C (en) | 1987-03-19 | 1994-03-01 | David Cullis-Hill | Anti-inflamatory compounds and compositions |
US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
US5263984A (en) | 1987-07-20 | 1993-11-23 | Regen Biologics, Inc. | Prosthetic ligaments |
FR2609397B1 (fr) | 1988-02-23 | 1991-12-13 | Serobiologiques Lab Sa | Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique |
US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
GB8900812D0 (en) | 1989-01-14 | 1989-03-08 | Univ Manchester | Pharmaceutical method and compositions |
FR2649982B1 (fr) | 1989-07-20 | 1991-09-27 | Inst Nat Sante Rech Med | Membrane biologique artificielle |
US5141928B1 (en) | 1989-12-20 | 1995-11-14 | Brujo Inc | Ophthalmic medication |
DE3942081A1 (de) | 1989-12-20 | 1991-06-27 | Behringwerke Ag | Mittel zur verbesserung der wiederfindung von annexinen |
US5514667A (en) | 1990-11-05 | 1996-05-07 | Arthropharm Pty. Limited | Method for topical treatment of herpes infections |
AU1052492A (en) | 1991-01-31 | 1992-08-06 | Farmitalia Carlo Erba S.R.L. | Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
IT1260137B (it) | 1992-04-17 | 1996-03-28 | Alfa Wassermann Spa | Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato |
ATE173627T1 (de) | 1992-09-04 | 1998-12-15 | Fuji Chem Ind Co Ltd | Medizinische zusammensetzung |
IT1264102B1 (it) | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali |
IT1264101B1 (it) | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 |
US5364845C1 (en) * | 1993-03-31 | 2002-09-10 | Nutramax Lab Inc | Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue |
US5691325A (en) | 1994-01-14 | 1997-11-25 | Sandyk; Reuven | Method for ameliorating age-related disease conditions |
US5597575A (en) | 1994-06-06 | 1997-01-28 | Breitbarth; Richard | Composition for stimulating and inducing hair growth |
US5639787A (en) | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
EP1221615A2 (de) * | 1995-04-25 | 2002-07-10 | Oridigm Corporation | S-Adenosyl-Methionin-Regulierung in Metabolismen und deren Verwendung in der Diagnostik und Therapie |
JPH11507621A (ja) | 1995-06-07 | 1999-07-06 | モンサント カンパニー | 置換ポリアザ大環状化合物の製造法 |
US5643892A (en) | 1995-06-07 | 1997-07-01 | Baker Norton Pharmaceuticals, Inc. | Method of treating chronic progressive vascular diseases |
GB2317109B (en) * | 1996-08-28 | 2000-06-21 | Farmsense | A therapeutic composition for the treatment and repair of connective tissue in mammals |
-
1997
- 1997-04-28 US US08/845,852 patent/US6255295B1/en not_active Expired - Lifetime
-
1998
- 1998-04-17 ES ES98915591T patent/ES2324565T3/es not_active Expired - Lifetime
- 1998-04-17 NZ NZ500025A patent/NZ500025A/en not_active IP Right Cessation
- 1998-04-17 AU AU69733/98A patent/AU747595B2/en not_active Expired
- 1998-04-17 DK DK98915591T patent/DK0979090T3/da active
- 1998-04-17 AT AT98915591T patent/ATE425757T1/de active
- 1998-04-17 DE DE69840668T patent/DE69840668D1/de not_active Expired - Lifetime
- 1998-04-17 WO PCT/US1998/007561 patent/WO1998048816A1/en active IP Right Grant
- 1998-04-17 PT PT98915591T patent/PT979090E/pt unknown
- 1998-04-17 EP EP07075664A patent/EP1849471B1/de not_active Expired - Lifetime
- 1998-04-17 DE DE69842021T patent/DE69842021D1/de not_active Expired - Lifetime
- 1998-04-17 CA CA002286552A patent/CA2286552C/en not_active Expired - Fee Related
- 1998-04-17 EP EP98915591A patent/EP0979090B1/de not_active Expired - Lifetime
- 1998-04-17 ES ES07075664T patent/ES2357255T3/es not_active Expired - Lifetime
- 1998-04-17 AT AT07075664T patent/ATE489099T1/de not_active IP Right Cessation
- 1998-04-17 CA CA002539919A patent/CA2539919A1/en not_active Abandoned
- 1998-04-17 CA CA002539696A patent/CA2539696A1/en active Pending
-
2008
- 2008-04-30 HK HK08104826.4A patent/HK1114774A1/xx not_active IP Right Cessation
-
2009
- 2009-05-13 CY CY20091100511T patent/CY1109064T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT979090E (pt) | 2009-05-04 |
AU747595B2 (en) | 2002-05-16 |
EP0979090A1 (de) | 2000-02-16 |
WO1998048816A1 (en) | 1998-11-05 |
US6255295B1 (en) | 2001-07-03 |
EP1849471B1 (de) | 2010-11-24 |
EP0979090B1 (de) | 2009-03-18 |
NZ500025A (en) | 2002-03-01 |
EP1849471A1 (de) | 2007-10-31 |
DK0979090T3 (da) | 2009-06-08 |
HK1114774A1 (en) | 2008-11-14 |
ES2357255T3 (es) | 2011-04-20 |
ES2324565T3 (es) | 2009-08-10 |
CA2286552C (en) | 2007-10-30 |
DE69840668D1 (de) | 2009-04-30 |
EP0979090A4 (de) | 2000-10-18 |
CA2539696A1 (en) | 1998-11-05 |
CA2286552A1 (en) | 1998-11-05 |
CY1109064T1 (el) | 2014-07-02 |
ATE425757T1 (de) | 2009-04-15 |
AU6973398A (en) | 1998-11-24 |
CA2539919A1 (en) | 1998-11-05 |
DE69842021D1 (de) | 2011-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE489099T1 (de) | Aminozucker, chondroitin und s-adenosylmethionin enthaltende zusammensetzungen | |
ES2374157T3 (es) | Tratamiento para la sinovitis traumática y el cartílago articular dañado. | |
CA2159591A1 (en) | Aminosugar and Glycosaminoglycan Composition for the Treatment and Repair of Connective Tissue | |
US20100330198A1 (en) | Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue | |
BR0009651A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas | |
AU3435497A (en) | Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies | |
BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
BG103430A (en) | FACTOR Xa INHIBITING HETEROCYCLIC DERIVATIVES | |
BR0010380A (pt) | Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos | |
NZ577602A (en) | A composition for treatment of connective tissues | |
BRPI9915480B8 (pt) | azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos. | |
BR9809492A (pt) | Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma | |
BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
BR9814498A (pt) | Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica | |
BR0010381A (pt) | Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina | |
UA42722C2 (uk) | Сульфіди, сульфоксиди або сульфони, або їх фармацевтично прийнятні солі і фармацевтична композиція, що їх містить | |
NZ514425A (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration | |
Mejersjö et al. | Effect of corticosteroid and sodium hyaluronate on induced joint lesions in the guinea-pig knee | |
CA2314817A1 (en) | Synergistic agents for enhancing tissue repair | |
Cylwik et al. | The influence of doxycycline on articular cartilage in experimental osteoarthrosis induced by iodoacetate | |
Canapp | Medical management of osteoarthrosis. | |
CA2446615A1 (en) | Nutritional composition for the treatment of connective tissue | |
SE9502265D0 (sv) | Användning av substituerade pentos- eller hexosderivat, som fysiologiskt aktiva substanser samt komposition innehållande dessa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |